Publicaciones científicas

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

Perez-Gracia JL (1), Loriot Y (2), Rosenberg JE (3), Powles T (4), Necchi A (5), Hussain SA (6), Morales-Barrera R (7), Retz MM (8), Niegisch G (9), Durán I (10), Théodore C (11), Grande E (12), Shen X (13), Wang J (13), Nelson B (13), Derleth CL (13), van der Heijden MS (14).

(1) Clínica Universidad de Navarra, Pamplona, Spain.
(2) Gustave Roussy, Université Paris-Saclay, Département de Médecine, Villejuif, France.
(3) Memorial Sloan Kettering Cancer Center, New York, NY, USA.
(4) Barts Cancer Institute, Queen Mary University of London, London, UK.
(5) Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
(6) Plymouth University, Peninsula Schools of Medicine and Dentistry, Plymouth University Hospitals NHS Trust, Devon, UK.
(7) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
(8) Urologische Klinik und Poliklinik, Technical University Munich, Munich, Germany.
(9) Department of Urology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
(10) Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del  Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
(11) Department of Oncology, Hôpital Foch, Suresnes, France.
(12) Hospital Universitario Ramón y Cajal, Madrid, Spain.
(13) Genentech, Inc., South San Francisco, CA, USA.
(14) Netherlands Cancer Institute, Amsterdam, the Netherlands.

Revista: European Urology

Fecha: 19-dic-2017

Oncología Médica

BACKGROUND:

Patients with metastatic urothelial carcinoma (mUC) who progress after platinum-based chemotherapy have had few treatment options and uniformly poor outcomes. Atezolizumab (anti-programmed death-ligand 1) was approved in the USA for cisplatin-ineligible and platinum-treated mUC based on IMvigor210, a phase 2, single-arm, two-cohort study.

OBJECTIVE:

To evaluate the efficacy and safety of atezolizumab by the number of prior lines of systemic therapy in patients with pretreated mUC.

DESIGN, SETTING, AND PARTICIPANTS:

IMvigor210 enrolled 315 patients with mUC with progression during or following platinum-based therapy at 70 international sites between May 2014 and November 2014. Key inclusion criteria included age ≥18 yr, creatinine clearance ≥30ml/min, and Eastern Cooperative Oncology Group performance status 0-1, with no limit on prior lines of treatment.

INTERVENTION:

Patients in this cohort received atezolizumab 1200mg intravenously every 3 wk until loss of clinical benefit.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

Centrally assessed Response Evaluation Criteria In Solid Tumors v1.1 objective response rate (ORR), median duration of response, overall survival (OS), and adverse events were evaluated by prior treatment. Potential differences between subgroups were evaluated using log-rank (for OS) and chi-square (for ORR and adverse events frequencies) testing.

RESULTS AND LIMITATIONS:

Three hundred and ten patients were efficacy and safety evaluable (median follow-up, 21 mo). Objective responses and prolonged OS occurred across all prespecified subgroups; median duration of response was not reached in most subgroups. In patients without prior systemic mUC therapy (first-line subgroup), ORR was 25% (95% confidence interval: 14-38), and median OS was 9.6 mo (95% confidence interval: 5.9-15.8). No significant differences in efficacy or toxicity by therapy line were observed.

CONCLUSIONS:

Atezolizumab demonstrated comparable efficacy and safety in previously treated patients with mUC across all lines of therapy evaluated.

PATIENT SUMMARY:

We investigated effects of previous treatment in patients with metastatic urothelial carcinoma that progressed after platinum-based therapy. Atezolizumab was active and tolerable no matter how many treatment regimens patients had received. ClinicalTrials.gov, NCT02108652.

CITA DEL ARTÍCULO  Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31015-1. doi: 10.1016/j.eururo.2017.11.023

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra